onc Videos

Videos

John Leonard, MD, Weill Cornell Medicine

Videos

New Developments in First- and Second-Line Treatments for Patients With Aggressive DLBCL

06/24/2022

John Leonard, MD, discusses recent therapeutic developments for aggressive DLBCL in the first- and second-line treatment settings, highlighting recent data around pelotuzumab vedotin and CAR-T therapies.

John Leonard, MD, discusses...

06/24/2022

Oncology

Videos

Rucaparib Maintenance Reduces Risk of Disease Progression in Platinum-Sensitive Ovarian Cancer

06/22/2022

Robert Coleman, MD, discusses findings from a post hoc exploratory analysis of the ARIEL3 trial, which further evaluated the efficacy and safety of rucaparib maintenance in patients with platinum-sensitive, recurrent ovarian carcinoma who are...

Robert Coleman, MD, discusses...

06/22/2022

Oncology

Michael Gnant, MD, Medical University of Vienna, Austria

Videos

Long-term Adjuvant Denosumab Reduces Treatment-Induced Fractures Among Patients With Breast Cancer

06/22/2022

Michael Gnant, MD, discusses findings from a study exploring long-term outcomes of adjuvant treatment with denosumab among patients with breast cancer receiving aromatase inhibitors.

Michael Gnant, MD, discusses...

06/22/2022

Oncology

Aleksandr Lazaryan, MD, Moffitt Cancer Center

Videos

First-Line Ofatumumab Plus Prednisone Demonstrates Promising Efficacy, Safety for Chronic GVHD

06/21/2022

Aleksandr Lazaryan, MD, PhD, MPH, discusses findings from a phase 2 study which explored the efficacy and safety of ofatumumab and prednisone as initial therapy for patients with chronic GVHD.

Aleksandr Lazaryan, MD, PhD,...

06/21/2022

Oncology

Videos

Trastuzumab Deruxtecan Reduces Risk of Disease Progression or Death by 50% in HER2-Low Metastatic Breast Cancer

06/21/2022

Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...

Debra Patt, MD, PhD, MBA,...

06/21/2022

Oncology

Videos

First-Line Rucaparib Maintenance Effective for Ovarian Cancer: ATHENA-MONO Trial

06/20/2022

Robert Coleman, MD, discusses findings from the phase 3 ATHENA-MONO trial which compared rucaparib vs placebo for maintenance therapy in patients with advanced-stage ovarian cancer.

Robert Coleman, MD, discusses...

06/20/2022

Oncology

Videos

Treating Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma

05/26/2022

Daniel Olson, MD, highlights a patient case of two non-melanoma skin cancers: cutaneous squamous cell carcinoma and basal cell carcinoma

Daniel Olson, MD, highlights a...

05/26/2022

Oncology

Videos

Treatment Approaches for Patients With Untreated and Relapsed MCL

05/23/2022

Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.

Tycel Phillips, MD, reviews...

05/23/2022

Oncology

Sarah Rutherford, MD, Weill Cornell Medicine

Videos

CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL

05/22/2022

Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.

Sarah Rutherford, MD, debates...

05/22/2022

Oncology

Preetesh Jain, MD, PhD, University of Texas MD Anderson Cancer Center

Videos

Ibrutinib Plus Rituximab Demonstrates Promising Efficacy in Older Patients With Previously Untreated MCL

05/15/2022

Preetesh Jain, MD, discusses results from a phase 2 trial exploring the efficacy and safety of ibrutinib plus rituximab for the first-line treatment of older patients with MCL.

Preetesh Jain, MD, discusses...

05/15/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology